|
全国免费电话：400-668-6834 -- 仅限中国地区 -- |
在线订购：QQ: 4006686834 电话订购：021-68591985 邮件订购：info@selleck.cn 我们也提供销售人员上门服务 |
技术支持电话：400-168-6834 我们将于一个工作日与您联系 |
Daratumumab (anti-CD38)
目录号：A2027 批次号: A202703
Daratumumab (anti-CD38) 是一种针对CD38的重组单克隆抗体。Daratumumab 是一种研究性的抗癌药物，适用于治疗多发性骨髓瘤的成年患者。MW =145.4 kDa。
抗体信息
| CAS号 | 945721-28-8 |
|---|---|
| 配制 | PBS Buffer, PH 7.4 |
| 推荐同型对照 | Human IgG1 |
| 来源 | Human |
| 储存条件 (自收到货起) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
| 除菌 | 0.2 μM filtered |
| 纯度 | 99% |
| 蛋白浓度 | 10.07 mg/ml |
| 内毒素 | ＜1EU/mg |
Daratumumab (anti-CD38)在文献中得到引用
| In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology [ Leuk Res, 2024, 147:107599] | PubMed: 39486120 |
| Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro [ Brain Behav Immun Health, 2024, 42:100865] | PubMed: 39411424 |
| Neutralization of BAFF and APRIL with engineered soluble BCMA decoy receptor for the treatment of B-cell malignancies [ Oxford University Research Archive, 2023, ] | PubMed: None |
| Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma [ J Exp Med, 2022, 219(9)e20220214] | PubMed: 35881112 |
| Aberrant BCMA signaling promotes tumor growth by altering protein translation machinery, a therapeutic target for the treatment of relapse/refractory multiple myeloma [ bioRxiv, 2022, 10.1101/2021.05.03.442500] | PubMed: None |
禁止用于人体及治疗！